Full Press Release Details
ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences:
Cantor Global Healthcare Conference (NYC)
Participation: Fireside chat and 1x1 investor meetings
Date/Time: Fireside Chat Wednesday, September 3, 2025, 3:20 PM ET
Webcast Link: Cantor/Axogen Fireside Chat
Wells Fargo Healthcare Conference (Boston)
Participation: 1x1 investor meetings only
Date/Time: Thursday, September 4, 2025
Morgan Stanley Annual Global Healthcare Conference (NYC)
Participation: 1x1 investor meetings only
Date/Time: Wednesday, September 10, 2025
Lake Street Best Ideas Growth (BIG 9) Conference (NYC)
Participation: 1x1 investor meetings only
Date/Time: Thursday, September 11, 2025
Webcast events can be accessed live through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, the replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine (pig) submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue healing. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea and several other countries.
For more information, visit www.axogeninc.com